Traditional Resistance to EGFR Inhibitors May Not Effect Responses With Amivantamab/Lazertinib in..
Dec 19, 2023
More than a third of patients who progressed on osimertinib (Tagrisso) therapy for EGFR-positive non–small cell lung cancer (NSCLC) had a response to the combination of amivantamab (Rybervant) plus lazertinib, according to results of a cohort of the CHRYSALIS trial (NCT02609776) presented during the 2021 ASCO Annual Meeting. Biomarker analysis in the cohort also helped to identify patients that may be more likely to respond to the combination, which may not be based solely on the underlying genetic mechanisms of resistance, presenter Byoung Chul Cho, MD, PhD, suggested. Amivantamab is a fully human bi-specific antibody targeting EGFR and MET that recently received FDA approval for the frontline treatment of adult patients with EGFR exon 20 insertion–mutant NSCLC. Lazertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI) that shows a promising safety profile, including low rates of EGFR-related toxicities.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…